Neutralizing Activity of BNT162b2-Elicited Serum

Yang Liu(The University of Texas Medical Branch at Galveston), Jianying Liu(The University of Texas Medical Branch at Galveston), Hongjie Xia(The University of Texas Medical Branch at Galveston), Xianwen Zhang(The University of Texas Medical Branch at Galveston), Camila R. Fontes-Garfias(The University of Texas Medical Branch at Galveston), Kena A. Swanson(Pfizer (United States)), Hui Cai(Pfizer (United States)), Ritu Sarkar(Pfizer (United States)), Wei Chen(Pfizer (United States)), Mark Cutler(Pfizer (United States)), David Cooper(Pfizer (United States)), Scott C. Weaver(The University of Texas Medical Branch at Galveston), Alexander Muik(BioNTech (Germany)), Uğur Şahin(BioNTech (Germany)), Kathrin U. Jansen(Pfizer (United States)), Xuping Xie(The University of Texas Medical Branch at Galveston), Philip R. Dormitzer(Pfizer (United States)), Pei‐Yong Shi(The University of Texas Medical Branch at Galveston)
New England Journal of Medicine
February 17, 2021
10.1056/nejmc2102017
Cited by 632Open Access
Full Text

Abstract

Variant SARS-CoV-2 and BNT162b2 Vaccine How well do serum samples obtained from persons injected with the BNT162b2 vaccine neutralize the P.1, B.1.1.7, and B.1.135 lineages of SARS-CoV-2, first ide...

Related Papers

No related papers found

Powered by citation graph analysis